NIAID Preclinical Development Support - Development of clade C Vaccine

这份合同将为NIAID提供广泛和灵活的非传统、前瞻性和面向开发的能力，当有前景的产品从研究人员发起的研究中出现时，为这些产品提供临床前开发支持。这些能力将使NIAID能够更快、更有效地缩小开发和生产差距。活动包括但不限于小规模生产、临床前测试和导致研究新药(IND)提交第一、第二和第三阶段临床测试的文件。主要目标是开发Ad41086 HIV Clade C包膜疫苗。

This contract will provide NIAID with a broad and flexible range of nontraditional, proactive and developmentally-oriented capabilities to provide preclinical development support for promising products when such products emerge from investigator-initiated research studies. These capabilities will allow NIAID to more rapidly and efficiently close development and production gaps. Activities include but are not limited to small-scale production, preclinical testing and documentation leading to Investigational New Drug (IND) submission for Phase I, II, and III clinical testing. The primary aim is for the development of a Ad4 1086 HIV Clade C envelope vaccine.